A phase I study to determine the maximum tolerated dose and safety of oral LR-103 (1{alpha},24(S)Dihydroxyvitamin D2) in patients with advanced cancer

Conclusion
Step A dose limiting toxicities limited accelerated dose escalation. The maximum tolerated dose of LR-103 was not reached prior to study termination and this agent is no longer being developed.

Source: Journal of Oncology Pharmacy Practice - October 25, 2015 Category: Cancer & Oncology Authors: Wisinski, K. B., Ledesma, W. M., Kolesar, J., Wilding, G., Liu, G., Douglas, J., Traynor, A. M., Albertini, M., Mulkerin, D., Bailey, H. H. Tags: Original Articles Source Type: research